TICKERNERD
Menu
ATRAATRAHealthcare · Biotechnology

ATRA Stock Forecast: Atara Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.70
+3.41% on the day

The 4 Wall Street analysts covering Atara Biotherapeutics, Inc. hold a median 12-month price target of $13 — +34.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$84.5M
Ticker Nerd rank
65 / 100
Median analyst target
$13
Analysts covering
4
Total return, dividends reinvested
1W
+19.9%
1M
+12.4%
YTD
−46.4%
1Y
−15.6%
From 52W high
−46.4%
From 52W low
+132.1%
$4
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atara Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
92
Size
76
Value
75
Quality
74
Revisions
56
Momentum
48
Accruals
47
Volatility
27
Growth
9

Issuance (92): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26ATRAHigh $18Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $10Median $13High $18

The green dot is the last close — the median target sits +34.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026Freedom BrokerUpgradeHold$4.00 → $10
8 May 2026Canaccord GenuityUpgradeBuy—
21 Jan 2026Freedom BrokerDowngradeSell—
13 Jan 2026Canaccord GenuityDowngradeHold—
19 Dec 2025Canaccord GenuityMaintainsBuy—
11 Mar 2025Canaccord GenuityMaintainsBuy—
28 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
22 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
17 Jan 2025Canaccord GenuityMaintainsBuy—
20 Dec 2024Rodman & RenshawInitiatesBuy—
13 Nov 2024Canaccord GenuityMaintainsBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
16 Aug 2024MizuhoUpgradeOutperform—
13 Aug 2024Canaccord GenuityMaintainsBuy—
17 July 2024Goldman SachsMaintainsSell—
22 May 2024HC Wainwright & Co.ReiteratesNeutral—
1 Apr 2024StifelMaintainsHold—
10 Nov 2023Goldman SachsMaintainsSell—
9 Nov 2023Evercore ISI GroupDowngradeIn-Line—
9 Nov 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Atara Biotherapeutics, Inc. (ATRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
15.3×

Cheaper than 11% of US stocks

Price / book
−3.6×

Cheaper than 96% of US stocks

EV / EBITDA
−8.5×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−96.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−99.5%

Higher than 2% of US stocks

Gross margin
76.0%

Higher than 88% of US stocks

Operating margin
−627.5%

Higher than 7% of US stocks

Net margin
−269.4%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−84.9%

Higher than 15% of US stocks

Return on assets
−24.1%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATRAAtara Biotherapeutics, Inc.$84.5M
65
PYPDPolyPid Ltd.$97.3M
50
YARWYarrow Bioscience, Inc.$97.2M
51
PTHSPelthos Therapeutics, Inc.$97.7M
21
BMEABiomea Fusion, Inc.$96.9M
50
FBIOFortress Biotech, Inc.$95.3M
78
CGTXCognition Therapeutics, Inc.$94.7M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atara Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATRA news & analysis

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Business Wire · 12 Aug 2026neutral

Atara Biotherapeutics reported its financial results for the second quarter of 2026 and provided business updates. The company noted it and its partner, Pierre Fabre Pharmaceuticals, held a productive Type A meeting with regulators during the quarter.

Why it matters — ATRA watchers would care because the quarterly update and the productive Type A meeting with partner Pierre Fabre signal progress in the company's regulatory and development efforts.

FAQ

Frequently asked questions about ATRA stock

What is the ATRA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Atara Biotherapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATRA stock a buy right now?

Of the 4 analysts covering Atara Biotherapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atara Biotherapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATRA?

As at 22 Aug 2026, Atara Biotherapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (92 of 100).

Will ATRA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +34.0% from the last close, and Ticker Nerd's factor model ranks Atara Biotherapeutics, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATRA stock forecast for 2030?

No analyst covering Atara Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.

How has ATRA stock performed over the past year?

Atara Biotherapeutics, Inc. returned -15.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative cell therapies and immunotherapies for patients with serious diseases.

What is the latest news on ATRA?

The most recent item we track (Business Wire, 12 Aug 2026): "Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress". Atara Biotherapeutics reported its financial results for the second quarter of 2026 and provided business updates. The company noted it and its partner, Pierre Fabre Pharmaceuticals, held a productive Type A meeting with regulators during the quarter.

Company

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics Inc. is a biopharmaceutical company focused on developing innovative cell therapies and immunotherapies for patients with serious diseases. The company specializes in creating therapeutic solutions that address critical unmet medical needs across oncology and other disease areas. Atara Biotherapeutics leverages advanced cellular and molecular approaches to design treatments that can potentially offer significant clinical benefits. The company operates in the competitive biopharmaceutical sector, where it collaborates with research institutions, clinical partners, and investors to advance its pipeline of therapeutic candidates through development and regulatory pathways. Founded and headquartered in the United States, Atara Biotherapeutics represents the biotechnology industry's commitment to translating scientific innovation into transformative medical treatments for patients worldwide.

CEO Dr. Anhco Nguyen Ph.D. · 10 employees · United States · https://www.atarabio.com